Economic Burden And Treatments Of Progression To Metastatic Disease In Alk Plus Nsclc Patients

annie guerin,m sasane,jinchao zhang,k culver,alexander r macalalad,r nitulescu,e wu,katherine dea

DOI: https://doi.org/10.1016/j.ijrobp.2014.08.231

2014-01-01

Abstract:To investigate treatments (tx), healthcare resource utilization (HRU), and costs in patients (pts) with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who progressed to metastatic disease. Data from 3 large United States administrative databases were combined. Pts with a diagnosis (dx) of lung cancer and a prescription fill for crizotinib were identified as ALK+ NSCLC pts. Pts with a sufficient observation period (≥60 days before and ≥30 days after the first observed metastasis dx) and who had NSCLC progression (defined as NSCLC pts developing metastases >30 days after initial NSCLC dx) were selected to evaluate tx patterns, HRU, and costs. Tx were analyzed during the 30-day periods before and after the first observed metastasis dx in order to capture the latest tx used prior to progression and the first tx used for metastases. HRU and costs were analyzed during the preprogression (up to 1 year prior to first metastasis dx) and postprogression periods (after first metastasis dx). Among the 753 ALK+ NSCLC pts, 71.8% had metastases. The most prevalent sites were brain (33.6%), bone/bone marrow (33.6%), respiratory system (33.5%), lymph nodes (29.2%), and liver (17.4%). Among newly diagnosed ALK+NSCLC pts (n=210), mean time from NSCLC dx to first dx of metastasis was 85.7 days. Among these 210 newly diagnosed pts (no claim for NSCLC for at least 6 months prior to first NSCLC claim), 73 (34.8%) progressed >30 days after NSCLC dx and had sufficient follow up. The pre- and post-tx patterns, HRU, and costs were assessed in these 73 pts. Compared to pre progression, postprogression use of radiation therapy increased by 53.9% (from 17.8% to 27.4%), chemotherapy increased by 25.1% (from 21.9% to 27.4%), targeted therapies other than crizotinib (eg, bevacizumab, erlotinib) increased by 20.6% (from 6.8% to 8.2%), and crizotinib increased by 4.5% (from 28.8% to 30.1%). Before progression, pts incurred an average of 0.7 inpatient (IP) admissions and 14.6 outpatient (OP) visits per-pt-per-year (PPPY) compared to 3.5 and 31.5 postprogression, respectively. Mean total costs were $64,471 PPPY pre progression and $226,116 PPPY postprogression. Postprogression costs were mainly driven by IP, OP, and pharmacy costs. Preprogression, 39.7% of pts had ≥1 IP admission compared to 61.6% postprogression. Among pts with ≥1 IP visit postprogression, mean cost per IP stay was $28,729 with an average of 5.8 days (median=4.0 days). Brain, bone, liver, and additional lesions in lung were the key metastatic sites associated with progression in ALK+NSCLC. The majority of ALK+NSCLC pts incurred a substantial economic burden with progression to metastatic disease. Delaying progression may not only reduce costs but may also improve pt outcomes.